文献速递肿瘤 PET/CT

趋化因子受体靶向PET/CT在新诊断边缘区淋巴瘤患者中提供更优诊断性能:与[18F]FDG的头对头比较

Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-11-09

本研究纳入32例未经治疗的边缘区淋巴瘤(MZL)患者,在 median 2天内先后行[68Ga]Ga-PentixaFor(CXCR4靶向)与[18F]FDG PET/CT。基于患者分析,[68Ga]Ga-PentixaFor识别全部32例(100%)MZL表现,[18F]FDG识别25/32例(78.1%)。在122/256个双阳性靶病灶中,[68Ga]Ga-PentixaFor的SUVmax、SUVpeak及靶/本底比值(TBR)均高于[18F]FDG(P < 0.01)。

要点

  • 基于患者分析,[68Ga]Ga-PentixaFor识别32/32例(100%)MZL表现,[18F]FDG识别25/32例(78.1%)。
  • 256个靶病灶中127/256(49.6%)仅CXCR4靶向成像可见,仅7/256(2.7%)[18F]FDG可见而[68Ga]Ga-PentixaFor漏检。
  • 122/256(47.7%)双阳性靶病灶中,[68Ga]Ga-PentixaFor的SUVmax、SUVpeak及TBR均高于[18F]FDG(P < 0.01)。

核心结论

  • 在新诊断MZL患者中,[68Ga]Ga-PentixaFor较[18F]FDG识别更多病变部位,且不依赖MZL亚型;定量PET参数包括TBR在[68Ga]Ga-PentixaFor PET/CT上更高,提示趋化因子受体靶向成像可改善诊断判读。

研究设计与样本

  • 研究纳入32例未经治疗的MZL患者(结内型17例、结外型13例、脾型2例),在 median 2天内接受[68Ga]Ga-PentixaFor与[18F]FDG PET/CT,对全部靶病灶进行视觉比较,对双阳性靶病灶进行SUVmax、SUVpeak及TBR定量分析,并进行MZL亚型分析。

主要发现

  • 基于患者分析,[68Ga]Ga-PentixaFor识别32/32例(100%)MZL表现,[18F]FDG识别25/32例(78.1%);256个靶病灶中127/256(49.6%)仅CXCR4靶向成像可见,仅7/256(2.7%)[18F]FDG可见而[68Ga]Ga-PentixaFor漏检;122/256(47.7%)双阳性靶病灶中,[68Ga]Ga-PentixaFor的SUVmax为10.3(范围2.53-37.2)vs [18F]FDG 5.72(范围2.32-37.0),SUVpeak为6.23(范围1.58-25.7)vs 3.87(范围1.54-27.7),P < 0.01;TBR中位数3.85(范围1.05-16.0)vs 2.08(范围0.81-28.8),约高1.8倍,P < 0.01;上述图像对比度差异由结内型MZL驱动(P < 0.01),结外型MZL仅接近显著性(P = 0.06)。

局限性

  • 原文结论指出上述发现提示趋化因子受体靶向成像可改善诊断判读,但未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with marginal zone lymphoma (MZL), [18F]FDG PET/CT provided inconsistent diagnostic accuracy. C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in MZL and thus, may emerge as novel theranostic target. We aimed to evaluate the diagnostic performance of CXCR4-targeting [68Ga]Ga-PentixaFor when compared to [18F]FDG PET/CT in MZL. METHODS: Thirty-two untreated MZL patients (nodal, n = 17; extranodal, n = 13; splenic, n = 2) received [68Ga]Ga-PentixaFor and [18F]FDG PET/CT within median 2 days. We performed a visual and quantitative analysis of the total lymphoma volume by measuring maximum/peak standardized uptake values (SUVmax/peak), and calculating target-to-background ratios (TBR, defined as lesion-based SUVpeak divided by SUVmean from blood pool). Visual comparisons for both radiotracers were carried out for all target lesions (TL), and quantitative analysis of concordant TL evident on both scans. Last, MZL subtype analyses were also conducted. RESULTS: On a patient-based level, [68Ga]Ga-PentixaFor identified MZL manifestations in 32 (100%) subjects (vs. [18F]FDG, 25/32 [78.1%]). Of the 256 identified TL, 127/256 (49.6%) manifestations were evident only on CXCR4-directed imaging, while only 7/256 (2.7%) were identified on [18F]FDG but missed by [68Ga]Ga-PentixaFor. In the remaining 122/256 (47.7%) concordant TL, [68Ga]Ga-PentixaFor consistently provided increased metrics when compared to [18F]FDG: SUVmax, 10.3 (range, 2.53-37.2) vs. 5.72 (2.32-37.0); SUVpeak, 6.23 (1.58-25.7) vs. 3.87 (1.54-27.7); P < 0.01, respectively. Concordant TL TBR on [68Ga]Ga-PentixaFor (median, 3.85; range, 1.05-16.0) was also approximately 1.8-fold higher relative to [18F]FDG (median, 2.08; range, 0.81-28.8; P < 0.01). Those findings on image contrast, however, were driven by nodal MZL (P < 0.01), and just missed significance for extranodal MZL (P = 0.06). CONCLUSIONS: In newly diagnosed MZL patients, [68Ga]Ga-PentixaFor identified more sites of disease when compared to [18F]FDG, irrespective of MZL subtype. Quantitative PET parameters including TBR were also higher on [68Ga]Ga-PentixaFor PET/CT, suggesting improved diagnostic read-out using chemokine receptor-targeted imaging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kosmala A, Duell J, Schneid S, et al. Chemokine receptor-targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG. Eur J Nucl Med Mol Imaging. 2023. PMID: 37943339. doi:10.1007/s00259-023-06489-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。